BLFS
HoldPremium GrowerBioLife Solutions, Inc. · Healthcare · United States · $1.8B · Avg Vol: $29M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
ABOUT BIOLIFE SOLUTIONS, INC.
Read
BioLife Solutions, Inc. provides proprietary biopreservation media, thawing devices, and cloud-based cold chain management solutions for the cell and gene therapy markets. As a market leader, its proprietary media and thawing technologies are becoming industry standards for cell and gene therapy clinical trials and commercialization, creating significant customer stickiness. The company serves nearly all major cell and gene therapy clinical trials globally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.2M | 68.0M | 74.6M | 96.2M | 8.1% | 106.7M | 115.2M | 134.8M | 18.4% |
| EPS | -3.29 | -1.55 | -0.44 | -0.09 | — | 1.00 | — | — | — |
| Shares | 42.8M | 45.2M | 46.9M | 48.2M | +12.5% | 48.9M | — | — | — |
| Debt | 43.7M | 33.8M | 30.0M | 17.9M | -25.7% | 15.7M | — | — | — |
| Equity | 364.2M | 337.7M | 348.9M | 371.9M | 0.7% | — | — | — | — |
| Op CF | -8.5M | -12.5M | 8.4M | 20.1M | 138.6% | 16.9M | — | — | — |
| Inv CF | -58.1M | 17.8M | 58.3M | -71.5M | — | — | — | — | — |
| Fin CF | 16.3M | 10.6M | -6.8M | -10.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLFS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLFS | BioLife Solutions, Inc.(you) | $1.8B | 50 | Hold |
| LMAT | LeMaitre Vascular, Inc. | $1.8B | 53 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| XRAY | DENTSPLY SIRONA Inc. | $2.2B | 58 | Hold |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| ATRC | AtriCure, Inc. | $2.5B | 64 | Hold |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| WRBY | Warby Parker Inc. | $3.1B | 34 | Sell |
| KMTS | Kestra Medical Technologies, Ltd. | $1.5B | 26 | Sell |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
Peer medians: ROE -31.0% · P/E 25.0x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.